See­los Ther­a­peu­tics 'tem­porar­i­ly' stops study in rare neu­ro dis­or­der for busi­ness rea­sons

Mi­cro­cap biotech See­los Ther­a­peu­tics is halt­ing en­roll­ment of its study in spin­ocere­bel­lar atax­ia type 3 (al­so known as Macha­do-Joseph dis­ease) be­cause of “fi­nan­cial con­sid­er­a­tions,” and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER